Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanyTMLCF Peter Lynch Fair Value is $0.03 as of Aug. 23, 2026, which is 98% below its 10-year median of 1.75. The stock has 3 warning signs investors should review. Among 262 Drug Manufacturers companies, The More Life Company ranks worse than 81.3% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, The More Life Company's PEG is 1. The More Life Company's 5-Year TTM EBITDA Growth Rate is 25.
The More Life Company's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Therefore, the Peter Lynch Fair Value for today is $0.03.
The historical rank and industry rank for The More Life Company's Peter Lynch Fair Value or its related term are showing as below:
TMLCF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.83 Med: 1.75 Max: 2.89
Current: 2.89
During the past 7 years, the highest Price to Peter Lynch Fair Value Ratio of The More Life Company was 2.89. The lowest was 0.83. And the median was 1.75.
TMLCF's Price-to-Peter-Lynch-Fair-Value is ranked worse than 81.3% of 262
companies
in the Drug Manufacturers industry
Industry Median: 1.25
vs TMLCF: 2.89
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
The More Life Company (OTCPK:TMLCF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
The More Life Company's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
0.0577
/
0.03
=
2.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The More Life Company Peter Lynch Fair Value Related Terms
The More Life Company Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for The More Life Company's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The More Life Company Peter Lynch Fair Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company Price-to-Peter-Lynch-Fair-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where The More Life Company's Price-to-Peter-Lynch-Fair-Value falls into.
The More Life Company's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
The More Life Company (TMLCF) has a Peter Lynch Fair Value of $0.03 as of Aug. 23, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on The More Life Company and its competitors. This is 98% below median its historical median of 1.75. Over the past decade, The More Life Company's Peter Lynch Fair Value has ranged from 0.83 to 2.89. According to the industry distribution chart, The More Life Company ranks #213 out of 262 companies in the Drug Manufacturers industry, placing it in the top 81.3%.
Is The More Life Company's Peter Lynch Fair Value too high?
The More Life Company's current Peter Lynch Fair Value of $0.03 is 98% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 2.89. The Drug Manufacturers industry median Peter Lynch Fair Value is 1.25. The More Life Company's value of $0.03 is 97.6% below this industry median. Based on the distribution chart, The More Life Company ranks #213 out of 262 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does The More Life Company's Peter Lynch Fair Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #213 out of 262 companies for Peter Lynch Fair Value. This places The More Life Company in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.25. The More Life Company's value of $0.03 is 97.6% below this benchmark. Historically, The More Life Company's own Peter Lynch Fair Value has ranged from 0.83 to 2.89 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.25, The More Life Company has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Drug Manufacturers company?
The median Peter Lynch Fair Value among Drug Manufacturers companies is 1.25, based on 262 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The More Life Company's current Peter Lynch Fair Value of $0.03 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on The More Life Company and its competitors. For the Drug Manufacturers industry, the median Peter Lynch Fair Value is 1.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The More Life Company's current Peter Lynch Fair Value is $0.03, which is 98% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (TMLCF) has a current Peter Lynch Fair Value of $0.03. The current Peter Lynch Fair Value is $0.03, which is 98% below median its 10-year median of 1.75 and 97.6% below the Drug Manufacturers industry median of 1.25. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For The More Life Company (TMLCF), the current Peter Lynch Fair Value is $0.03 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMLCF has been successfully added to your 
